Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline


Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

The FDA has accepted with Priority Review Cubist’s New Drug Application for investigational antibiotic ceftolozane/tazobactam, for which the Company is seeking FDA approval for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections…


News & Press

8 Aug

Cubist’s Once-daily SIVEXTRO™ (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations

SIVEXTRO is a short, six-day course of therapy to treat serious skin infections, including those caused by MRSA

Cubist Pharmaceuticals, Inc. announces SIVEXTRO™ (tedizolid phosphate) indicated for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI) is now available in the U.S. in once-daily I.V. and oral formulations.

Careers at Cubist


Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…